We are excited to publish a collection entitled Stem Cell Plasticity in Tissue Repair and Regeneration, which results from a PLOS ONE’s call for papers announced last year. We encouraged submissions spanning a broad range of biomedical topics, including basic stem cell biology, preclinical research and biomedical engineering. The papers included in the collection provide examples of how the dynamic functions of stem cells can be harnessed to regenerate damaged or lost tissues. Regenerative approaches may offer a unique therapeutic opportunity for diseases where with no established treatments exist.
In line with PLOS ONE publication ethos, we welcomed solid and clearly reported studies regardless of the perceived impact and positive nature of the main findings. We think that in the fast-paced field of stem cell research, addressing publication bias is particularly important to advance knowledge and bring new therapies to the clinic.
Two studies included in the collection reported the role and regenerative ability of adult mesenchymal stem cells (MSCs). Chung et al. showed the regenerative potential of human MSCs in a rat model of bladder disease. They also identified the bladder submucosa as the most effective route of MSC administration. In a clinical study among patients with acute respiratory distress syndrome, Patry et al. found that extracorporeal membrane oxygenation increased the number of circulating MSCs, although further research is needed to establish the regenerative potential of these cells in the context of pulmonary disease.
Two methodological papers focused on the differentiation of human induced pluripotent stem cells (hiPSCs) into cardiac cells. This rapidly evolving research area aims at overcoming the current challenges in generating mature cells in large quantity and high purity for tissue engineering applications. Rupert et al. described practical methods for the optimization of hiPSC-cardiomyocyte differentiation, highlighting the key role of metabolic selection. Chu et al. demonstrated that cardiac differentiation can be achieved by co-culturing hiPSCs with mature cardiomyocytes, without the addition of exogenous pharmacological agents.
This collection was made possible thanks to the fantastic work of our Guest Editors – Michelina Iacovino, Scott D. Olson and Che Connon – who helped develop the scope of the call for papers and evaluated all submitted research for inclusion in the collection. We are also extremely grateful to the members of our editorial board and external peer-reviewers for dedicating their time and expertise to the evaluation of submissions.
We will add new papers to the Collection as they are published, so we invite you to check back the collection webpage in the coming weeks. If you are interested in keeping up to date with the latest stem cell research from the broader literature, check out our PLOS Channel too.
Scott D. Olson
Scott Olson is a mesenchymal stem cell (MSC) Biologist working in the Children’s Program in Regenerative Medicine in the Department of Pediatric Surgery at McGovern School of Medicine. Dr. Olson completed his doctorate in the lab of Dr. Darwin Prockop at Tulane University’s Center for Gene Therapy studying novel methods by which MSCs can contribute to tissue repair. At University of California at Davis’s Health Sciences Institute for Regenerative Cures with Dr. Jan Nolta, Dr. Olson worked to apply MSCs as a platform to develop new treatments for Huntington’s Disease. Dr. Olson joined UTHealth in September 2011.
Dr. Olson is involved in developing and transitioning studies with direct translational applications. At UT Health, his primary focus is bringing his expertise in the field of adult stem cells, specifically MSCs, to explore their potential in the treatment of Traumatic Brain Injury (TBI) and in trauma-associated neuroinflammation in general. MSCs have been used in a number of completed, ongoing, and proposed clinical trials with reported therapeutic benefits. Dr. Olson strives to better describe the role of MSCs in injuries of the central nervous system, highlighting their innate therapeutic abilities in an effort to create an improved treatment for TBI.
Michelina Iacovino is an Assistant Professor at the David Geffen School of Medicine at The University of California, Los Angeles (UCLA), and a Principal Investigator at Los Angeles Biomedical Research Institute (LABioMed) at Harbor-UCLA in the Pediatrics Department.
She obtained her Doctorate in Italy in Biochemistry and Applied Chemistry working on mitochondrial DNA inheritance in yeast in collaboration with Dr. Ronal Butow at the University of Texas Southwestern Medical Center. She then trained in the field of hematopoietic stem cells with Dr. Michael Kyba during her postdoctoral fellowship, studying the role of Hox genes during blood development. She joined LABioMed in 2012, extending her expertise of stem cell biology to develop treatments for rare lysosomal disorders that affect brain function. She is currently developing a stem cell therapy for Sanfilippo syndrome, an incurable and rare lysosomal disorder, using neural progenitor cells.
Che Connon obtained his PhD in Biophysics from the Open University Oxford Research Unit in 2000, during which time (under the supervision of Professor Keith Meek) he investigated corneal wound healing and transparency. He subsequently obtained a JSPS post-doctoral fellowship to work with Professor Shigeru Kinoshita in Kyoto, Japan for two years studying corneal stem cell transplantation. Upon his return to the UK he was awarded a Royal Society Fellowship to investigate the use of biomaterials in stem cell therapies. He obtained his first permanent position in 2007 at University of Reading, School of Pharmacy and since 2014 he has held the position of Professor of Tissue Engineering at Newcastle University.
Professor Connon’s research team seeks to engineer functional replacement and temporary ‘bridge’ tissues using a modular approach while also developing model systems to study physiological and pathophysiological corneal tissue formation. He is currently working with smart (cell responsive) biomaterials, characterizing the mechanical and geometric environment of the corneal stem cell niche and 3D printing the corneal stroma.